Acute myeloid leukemia (AML) remains a therapeutic challenge despite increasing knowledge about the molecular origins of the disease, as the mechanisms of AML cell escape from chemotherapy remain poorly defined. We hypothesized that AML cells are addicted to molecular pathways in the context of chemotherapy and used complementary approaches to identify these addictions. Using novel molecular and computational approaches, we performed genome-wide short-hairpin RNA screens to identify proteins that mediate AML cell fate after cytarabine exposure; gene expression profiling of AML cells exposed to cytarabine to identify genes with induced expression in this context; and examination of existing gene expression data from primary patient samples. Integration of these independent analyses strongly implicates cell-cycle checkpoint proteins, particularly WEE1, as critical mediators of AML cell survival after cytarabine exposure. Knockdown of WEE1 in a secondary screen confirmed its role in AML cell survival. Pharmacologic inhibition of WEE1 in AML cell lines and primary cells is synergistic with cytarabine. Further experiments demonstrate that inhibition of WEE1 prevents S-phase arrest induced by cytarabine, broadening the functions of WEE1 that may be exploited therapeutically. These data highlight the power of integrating functional and descriptive genomics, and identify WEE1 as a potential therapeutic target in AML.
INTRODUCTION
In aggregate, acute myeloid leukemia (AML) continues to have the lowest survival rates of all leukemias. 1 In children with AML, long-term survival rates for all patients average about 50 --60%, survival rates for adults are generally worse, and fewer than 10% of elderly patients survive long-term after diagnosis of AML. 1, 2 AML is highly molecularly heterogeneous and data suggest that at least two cooperating mutations resulting in impaired differentiation (class-II mutation), and enhanced proliferation or survival (class-I mutation), are required for AML genesis. 3 Rearrangement of the mixed-lineage leukemia gene is an example of class-II mutation, whereas mutations of several kinases, including Flt3 and c-Kit, are examples of class-I mutations. 3 While the clinical and molecular features of AML can be used to predict response to therapy, with notable exceptions, this information is not used to guide therapy. For over three decades, treatment has remained dependent on remission induction using cytarabine (ARA-C) and an anthracycline like daunorubicin. 4 While attempts to optimize doses of cytotoxic chemotherapeutics have improved outcomes, 5 some studies suggest that dose limits may have been reached and that new agents are needed to further improve outcomes. 6 --8 ARA-C and daunorubicin are conventional chemotherapeutics with multiple mechanisms of action. 9 Although some of the mechanisms of cell death in AML cells exposed to these drugs have been determined, the mechanisms by which a minority of cells survives are not as well understood. 10 Traditional approaches to studying cancer have resulted in dramatic improvements in outcomes for certain populations. The quintessential success of the candidate gene approach is that of chronic myeloid leukemia, for which the oncogene BCR-ABL was discovered, its various functions determined and targeted therapy successfully translated into clinical care. 11 However, the majority of cancers, including AML, are much more molecularly heterogeneous than chronic myeloid leukemia, and candidate gene approaches are slow and cumbersome. Thus, novel approaches to more rapidly identify and validate mediators of cell survival have the potential to dramatically alter our understanding of cellular biology and develop novel therapeutic strategies. For example, short-hairpin RNA (shRNA) libraries have been used to identify positive and negative regulators of cancer cell survival with or without drug treatment. 12 --18 We have hypothesized that escape pathways become essential to cancer cell survival in the context of specific cancer therapy. Herein we describe the first genome-wide functional genetic screen in AML, which we undertook to identify such escape pathways. Integrating this functional assay with more descriptive analyses of the genome, we have identified that several proteins involved in cell-cycle checkpoints are critical mediators of AML cell fate after exposure to ARA-C. One of these molecules in particular, WEE1, can be inhibited pharmacologically, sensitizing AML cells to ARA-C. Contrary to studies in other cancers, inhibition of WEE1 abrogates the S-phase arrest induced by ARA-C, broadening the therapeutic potential of WEE1 inhibition. These studies highlight the power of integrating functional and descriptive genomics, and implicate WEE1 as a novel therapeutic target in AML.
MATERIALS AND METHODS

Lentivirus preparation
Virus containing medium was prepared as described previously. 19 For the genome-wide screen, the HIV based GeneNet Lentiviral Human 50K library was used (pSIH1-H1-Puro; System Biosciences, Mountain View, CA, USA) with minor modifications to the manufacturer's recommendations. For high-throughput and final validation, TRC HIV-based plasmids (pLKO.1) were used.
Cell culture
All cells were cultured at 37 1C in humidified air supplemented with 5% CO 2 . 293FT cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum and penicillin/streptomycin. Molm13, MV4-11 and U937 cells were cultured in RPMI with 10% fetal bovine serum and penicillin/streptomycin. The IC 75 of ARA-C for Molm13 and MV4-11 cells was determined to be 20 and 800 nM, respectively. Murine bone marrow cells were collected from the tibiae and femora of two C57Bl/6 mice and cultured in Iscove's Modified Dulbecco's Medium with 10% fetal bovine serum, and cytokines, as described previously. 19 Primary AML samples were collected after informed consent with approval of the Colorado Multiple Institutional Review Board. Ficoll-separated mononuclear cells were cultured in StemSpan SFEM (Stem Cell Technologies, Vancouver, BC, Canada) with 20% fetal bovine serum, initially at 0.6 --4 Â 10 5 /ml.
Genome-wide functional genetic screening
Transduction, puromycin selection and treatment of Molm13 and MV4-11 cells were performed using conditions optimized for each cell line. Three replicates each of untreated and ARA-C treated were incubated for 72 h. Five-fold more cells were ARA-C treated than left untreated to prevent stochastic loss of representation of shRNA tags. After drug exposure, cells were counted by propidium iodide (PI) (Sigma-Aldrich, St Louis, MO, USA) exclusion and flow cytometry (Guava EasyCyte Plus; Millipore, Billerica, MA, USA), re-plated in fresh medium without drug, and counted and re-plated every 72 h thereafter, until there were sufficient numbers of cells for harvest of RNA. shRNA tags were isolated and prepared for sequencing and quantification using the Illumina Genome Analyzer IIx (Illumina Inc., San Diego, CA, USA; see Supplementary information for more details).
Targeted high-throughput validation
Pooled, shRNA-expressing plasmids from the TRC1 and TRC1.5 libraries were provided through the Functional Genomics Core of the University of Colorado Cancer Center. If available, two shRNAs per target that were validated by TRC were included in the pool. If validated constructs were not available, five shRNAs per target were included. Transduced, puromycinselected Molm13 cells were left untreated or treated with ARA-C, with five replicates per condition. After recovery from treatment, shRNA tags were isolated, barcoded per replicate, and prepared for sequencing and quantification using the Illumina Genome Analyzer IIx (Supplementary information). Genes were considered validated if 1 of 2 shRNAs or if 2 of 3 or more shRNAs were statistically significantly differentially represented in the expected direction. P-values were generated using edgeR. 20 
Gene expression analysis
Molm13 cells were treated with 20 nM ARA-C for 24 h, total RNA was isolated, reverse-transcribed, analyzed using Affymetrix GeneChip Human Genome U133 Plus 2.0 microarray and data were analyzed as described previously. 21 The top 100 genes with the greatest changes in signal-tonoise ratios in either direction were considered in subsequent analyses. Oncomine (oncomine.org) was used to evaluate existing data sets for differential expression of a subset of genes using default settings. 22, 23 Pharmacologic validation ARA-C and hydroxyurea (HU) were purchased from Sigma-Aldrich; MK1775 from Axon Medchem (Groningen, The Netherlands) and WEE1 inhibitor II (BCHCD) from EMD Chemicals (Philadelphia, PA, USA). AML cells were diluted to 2 Â 10 5 cells/ml, and treated with ARA-C, HU, and/or MK1775 or BCHCD at the indicated concentrations, in duplicate or triplicate. A subset of these hits was included in a targeted sub-library for secondary screening. Selected hits were analyzed using Ingenuity Pathways Analysis, validated pharmacologically and the mechanism of cell fate was examined.
(b) Complementary analyses of differential shRNA tag representation. Data were analyzed by two independent processes. The BINGS pipeline used edgeR to identify differentially represented shRNA tags and then applied a weighted Z-score to rank genes as providing chemoresistance or chemosensitivity when inhibited (BINGS). A second method takes into consideration the absolute fold change of normalized shRNA tag counts and redundancy of shRNAs directed against a gene (RFC).
Dimethyl sulfoxide was maintained at less than 0.1% final concentration for all experiments. Cells were counted 72 h later by flow cytometry and PI exclusion. In some experiments, an aliquot of the remaining cells was diluted 1:10, re-plated, incubated for another 72 h and counted again. The extent of proliferation was calculated as described previously. 19 The extent of inhibition relative to dimethyl sulfoxide-treated cells was input into CalcuSyn (Biosoft, Cambridge, UK) to calculate combination index values.
Combination index values less than 1 are considered to represent synergistic inhibition of cellular proliferation. 24 Apoptosis was assessed using the GuavaNexin reagent (Millipore) and Guava EasyCyte Plus.
Cell-cycle analyses MV4-11 cells were treated as indicated for 48 h in duplicate, after which 5-bromodeoxyuridine (BrdU) was added at 10 mM for 1 h. Cells were then fixed, stained with a fluorescein isothiocyanate-linked anti-BrdU antibody and PI, and analyzed by flow cytometry as described previously. 25 Data were analyzed using Summit 5.0 (Dako North America, Carpinteria, CA, USA).
Antibodies
Antibodies directed against WEE1, cyclin-dependent kinase-2 (CDK2) and tubulin were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibodies directed against phospho-CDK2 (y15) were purchased from Abcam (Cambridge, MA, USA). Anti-actin antibody was purchased from Millipore. Anti-BrdU antibody was purchased from Dako North America.
Data analyses
Functional genetic screening data from the deep sequencer were preprocessed using software provided by Illumina. Sequences passing filters Unsupervised hierarchical clustering of unfiltered data demonstrates that within cell lines, shRNA tag representation clusters according to treatment condition, suggesting that differences in shRNA tag representation are due to treatment condition and are not stochastic. (b) Differential shRNA tag representation implicates mediators of AML cell fate after exposure to ARA-C. Heatmaps of data filtered for quality (BINGS method) show differential representation of shRNA tag counts by treatment condition. Mediators of chemosensitivity or chemoresistance are represented at either end. (c) Overlap between independent analysis parameters identifies hundreds of mediators of AML cell fate after exposure to ARA-C. The number of genes identified as hits with BINGS and RFC is indicated, as well as the overlap between the two methodologies. The overlapping subset is expected to be enriched for true positive hits.
for quality and vector-specific landmarks were mapped to shRNA tag libraries. edgeR was used to generate adjusted P-values for each tag, 20 and a modified Z-score was used to generate P-values and E-scores for each gene (Supplementary information) for the BINGS ranking of hits. For the RFC ranking, raw data counts were filtered, adjusted and normalized (Supplementary information), and genes for which more than one shRNA showed greater than three-fold over-or under-representation after ARA-C exposure were included. The statistical significance of the extent of overlap between hit lists was determined using 10 000 simulations on randomly selected genes. Java Treeview 26 was used to depict hierarchical clustering generated using an open-source clustering software. 27 Ingenuity IPA 9.0 (Ingenuity Systems, Redwood City, CA, USA; www.ingenuity.com) was used to identify networks and functions represented by shRNA tags in the list of hits. Excel and GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA)
were used for data sorting, analysis and graphical depiction of data. Student's t-test was used to compare two samples, whereas analysis of variance and Bonferroni's post-test were used to compare more than two samples. Error bars in each figure depict the standard error of the mean, and may be obscured when narrow.
RESULTS
Genome-wide functional genetic screen identifies mediators of AML cell fate after ARA-C exposure To identify proteins that mediate AML cell survival in the context of treatment with ARA-C, we developed a systematic approach, beginning with a genome-wide, functional genetic screen ( Figure 1a ) in two AML cell lines (Molm13 and MV4-11), both of which have Molm13 cells were transduced with an independent sub-library of shRNAs targeting a subset of 35 hits from the genome-wide screen, as well as negative control shRNAs targeting a non-coding sequence, the housekeeping gene HPRT, and functional controls CDA (which de-activates ARA-C) and DCK (which activates ARA-C). The cells were treated with ARA-C or left untreated, and shRNA tags were isolated and quantified as before. Each targeted gene is represented by a column, and each shRNA is represented by a row and color-coded for its representation in ARA-C: red (significantly under-represented), green (significantly over-represented) and gray (no change). Empty boxes reflect genes for which fewer than five shRNAs were included. The normalized fold change (nFC) of each shRNA in ARA-C is indicated within each box. Asterisks indicate genes considered validated. Daggers indicate genes for which shRNA representation was opposite of predicted. (b) Pathway analysis of synthetic lethal hits from the genome-wide screen identifies a cell-cycle network as critical in determination of AML cell fate after exposure to ARA-C. The top-scoring network in Ingenuity Pathways Analysis among proteins identified as chemosensitizing when inhibited is 'Cell Cycle, Cellular Growth and Proliferation, Cancer.' (c) Cell-cycle checkpoint proteins implicated in the genome-wide screen. Review of data from the genome-wide functional genetic screen revealed several other genes involved in cell-cycle checkpoints, for which there was at least one shRNA differentially represented in ARA-C-treated cells, but which may not have reached the threshold criteria to be included in the original list of hits. A schematic representation of their roles in cellcycle progression is presented, with cell-cycle inhibitors listed in red letters and cell-cycle promoters listed in green letters. The normalized fold change in representation in ARA-C-treated cells (and the cell line in which differential representation was noted) is listed next to the gene symbols. Asterisks indicate genes that met the criteria for inclusion in the overlapping list of hits from both analyses.
mixed-lineage leukemia rearrangement and FLT3 mutation. 28, 29 Two independent analysis approaches were applied ( Figure 1b ). Hierarchical clustering of unfiltered data demonstrates that within cell lines, replicates cluster by treatment condition, suggesting that shRNA tag representation is dependent on the treatment and is not stochastic (Figure 2a ). The relative representation of the shRNA tags was then compared, with the expectation that shRNAs tags under-represented after ARA-C exposure correspond to genes, which confer chemosensitivity when inhibited, whereas those which are over-represented correspond to genes, which confer chemoresistance (Figure 2b ). To identify 'hits' from this screen, we applied a novel statistical and mathematic ranking using a BioInformatics for Next Generation Sequencing pipeline (BINGS; Supplementary Table 1 ). To complement this, we also developed a hit list based on Redundancy of shRNAs targeting a gene and Fold-Change values over a threshold expected to have biologic relevance (RFC; Supplementary Table  2 ). These lists were compared and found to have significant overlap (Po0.0001; Figure 2c ). We surmised that genes common between the two analyses would be enriched for true positives and concentrated subsequent efforts on this list (Supplementary Table 3 ). Validation of hits from functional genetic screening is best performed using complementary and independent methods; however, these experiments can be cumbersome and timeconsuming when performed at a large scale. For example, to individually validate 10 chemosensitivity-and chemoresistanceconferring hits would necessitate the generation of over 100 clones in each cell line, followed by determination of sensitivity to ARA-C and the extent of gene knockdown. This list could be narrowed further based on published data regarding these genes, but to do so would be biased against genes that are understudied. Thus, we developed a strategy of unbiased, high-throughput validation using a sub-library of pooled shRNAs and a similar methodology as used for the original screen. Notably, the shRNAs for high-throughput validation are obtained from a source that uses an entirely different algorithm for shRNA design. 30 In this secondary screen, we confirmed that a number of the hits from the genome-wide screen do in fact mediate AML cell survival in the context of ARA-C treatment (Figure 3a ). There were nine genes confirmed to mediate chemosensitivity when inhibited and eight confirmed to confer chemoresistance, based on statistical analysis of expected differential representation. Upon closer analyses of these data, though, it is clear that our genome-wide screen analysis was more accurate in identifying sensitivity mediators than resistance mediators. For example, 11 genes expected to confer resistance when knocked down actually conferred sensitivity. Conversely, only three expected sensitivity mediators conferred resistance. Thus, subsequent efforts were concentrated on the list of genes identified as synthetic lethal with ARA-C.
Pathway analysis of synthetic lethal hits implicates cell-cycle regulation as a key determinant of AML cell fate in ARA-C We then analyzed the list of synthetic lethal hits using Ingenuity Pathways Analysis. The top-scoring network from this analysis is Figure 4 . Cell-cycle regulation proteins are induced in AML cells exposed to ARA-C and overexpressed in patient primary AML samples. (a) Gene expression profiling of AML cells exposed to ARA-C. Molm13 cells were treated with ARA-C or left untreated for 24 h at the IC 75 dose used in the functional genetic screen. Before initiation of widespread apoptosis, mRNA was harvested and analyzed by microarray. Whereas there was only a modest difference in global gene expression, the most differentially expressed genes are enriched for those involved in cell-cycle regulation as defined by Ingenuity Pathways Analysis. (b) A subset of chemosensitizing hits is over-represented in primary patient samples as compared with normal. Three independent data sets available in Oncomine were queried for the relative expression of chemosensitizing hits. Genes are listed left to right based on mean relative fold change compared with normal from the three data sets. The number of asterisks next to gene name indicates the number of data sets in which differential expression was determined to be statistically significant.
'Cell Cycle, Cellular Growth and Proliferation, Cancer' (Figure 3b ). The top Molecular and Cellular Function is 'Cell Cycle' with P-values as low as 7.16 Â 10 À6 (Supplementary Table 4 ). This analysis suggests that cell-cycle regulation is a key determinant of AML cell fate after ARA-C exposure. We returned to the original genome-wide screen, to look for additional genes that did not pass the criteria to be included as hits and with known function in cell-cycle regulation, focusing on those related to DNA-damage checkpoints. In so doing, we identified several more genes that may also mediate AML cell survival in the context of ARA-C treatment (Figure 3c ).
Expression of cell-cycle control proteins is induced in AML cells exposed to ARA-C We next asked whether there are changes in gene expression patterns in AML cells exposed to ARA-C, hypothesizing that genes induced in ARA-C and identified as chemosensitizing in the functional screens may be of particular importance in mediating AML cell survival. Molm13 cells were exposed to ARA-C for 24 h, after which RNA was extracted and analyzed by microarray (Figure 4a and Supplementary Table 5) . Surprisingly, there was only one gene (GOLGA2) that was identified as chemosensitizing and was differentially expressed in the presence of ARA-C. GOLGA2 did not appear to mediate AML cell fate in the secondary screen, though, and was not considered for further study. Despite lack of overlap at the molecular level, differentially regulated genes analyzed by Ingenuity Pathways Analysis identified 'Cell Cycle' as one of the top Molecular and Cellular functions represented by these genes with P-values as low as 5.89 Â 10 À4 (Supplementary Figure 1 ). The functional overlap of genes with altered expression and chemosensitivity when knocked down highlights the importance of cell-cycle control in determining AML cell fate after ARA-C exposure. WEE1 is expressed in human primary AML samples We next considered whether WEE1 and other molecules in our list of chemosensitizing genes are overexpressed in AML cells from primary patient samples, as compared with normal cells, with the hypothesis that differential expression may further implicate mediators of AML cell fate in ARA-C with therapeutic relevance. We used Oncomine to query existing gene expression data from primary patient samples. 31 Three data sets are available in this database from which gene However, when the two drugs were combined, inhibition of cellular proliferation was synergistic, as defined by the combination index (Table 1 ). (b) Addition of MK1775 to ARA-C eliminates AML cells to a greater extent than ARA-C alone. MV4-11 and Molm13 cells were treated with ARA-C, MK1775 (100 nM) or both for 72 h; counted; and re-seeded at 1/10 dilution without addition of drugs. Seventy-two hours later they were counted again. At these doses of ARA-C, some cells recover from treatment and begin to proliferate. However, addition of MK1775 appears to eliminate this population, as there is no evidence of proliferation at the 144-h time point (Po0.001 for MV4-11; P ¼ 0.05 for Molm13). (c) Inhibition of WEE1 sensitizes U937 cells to ARA-C. U937 cells were treated with ARA-C and/or MK1775, and counted as in Figure 6c . U937 cells show similar synergistic inhibition of proliferation with both drugs (Table 1 ; Po0.01). (d) Inhibition of WEE1 does not sensitize normal bone marrow cells to ARA-C. Murine whole bone marrow was cultured in cytokine-containing medium with ARA-C and/or MK1775 at the indicated concentrations for 72 h, counted and then allowed to recover for another 72 h without addition of more drugs.
(e) Inhibition of WEE1 by shRNA sensitizes Molm13 cells to ARA-C. Molm13 cells were transduced with a non-silencing shRNA (shF) or an shRNA directed against WEE1 (shWEE1). Knockdown of WEE1 was confirmed by western blotting (inset). Cells were treated with ARA-C at the indicated doses for 72 h and then allowed to recover for another 72 h in the absence of drug. ***Po0.001.
expression in AML cells can be compared with 'normal' cells. 32 --34 A subset of genes identified as chemosensitizing, including WEE1, appears to be significantly overexpressed in AML cells as compared with normal cells (Figure 4b ).
Inhibition of WEE1 sensitizes AML cell lines to the anti-proliferative effects of ARA-C The strongest hit from the genome-wide screen among cell-cycle control genes was WEE1, which was identified by both analysis techniques, confirmed in the secondary screen, included in the top-scoring Network and the top Molecular and Cellular Function as defined by pathways analysis, and is differentially expressed in AML cells as compared with normal. WEE1 is a dual specificity kinase, which in the context of DNA damage, phosphorylates CDK1 at tyrosine-15, inactivating the CDK1/cyclin B complex and preventing mitosis. 35 Inhibition of WEE1 is being explored therapeutically in solid tumors, but to our knowledge, has not been examined in AML. To further validate the role of WEE1 in AML cells exposed to ARA-C using non-genetic means, we used a small-molecule inhibitor of WEE1, MK1775. 36 Treatment with MK1775 alone has little effect on the proliferation of these cells, except at concentrations approaching 200 nM ( Supplementary  Figure 2a ). However, in combination with ARA-C, lower doses (20 --100 nM) of MK1775 are synergistic in inhibiting AML cellular proliferation after 72 h of treatment ( Figure 5a and Table 1 ). Consistent with this finding, when cells are removed from drug treatment after 72 h, AML cells recover from ARA-C at some doses, but addition of MK1775 prevents this recovery (Figure 5b ). We performed similar experiments in U937 cells, which do not have FLT3 mutation or mixed-lineage leukemia rearrangement, 29 and observed similar combinatorial activity of ARA-C with addition of the WEE1 inhibitor in U937 cells ( Figure 5c and Table 1 ), indicating that susceptibility to this combination of drugs is not specific to Flt3 dependence or mixed-lineage leukemia rearrangement. Treatment of murine hematopoietic progenitor cells ex vivo did not result in combinatorial inhibition of proliferation, suggesting that the combination may not be overly toxic to normal hematopoiesis (Figure 5d ). To ensure that the observed combinatorial effect is not an off-target effect of MK1775, we treated MV4-11 cells with ARA-C and a second WEE1 inhibitor (BCHCD), and again observed greater inhibition of cellular proliferation with WEE1 inhibition and ARA-C as compared with ARA-C alone (Supplementary Figure 2b) . In addition, we used shRNA to knockdown WEE1 in Molm13 cells and observed enhanced sensitivity to ARA-C in cells in which WEE1 had been knocked down compared with those expressing a non-silencing shRNA (Figure 5e ).
Inhibition of WEE1 abrogates S-phase replication checkpoint induced by ARA-C Identification and validation of WEE1 as a chemosensitizing target was somewhat surprising in that inhibition of WEE1 has primarily been examined in the context of abrogation of the G 2 /M checkpoint, 36, 37 whereas ARA-C induces G 1 or S-phase arrest. 38 To begin to understand the mechanism of the combinatorial effects of ARA-C and WEE1 inhibition, we performed cell-cycle analysis of MV4-11 cells by staining with PI for DNA content. At the doses used in these experiments, there was a considerable increase in the sub-G 1 population (Supplementary Figure 3a) , but little evidence of cell-cycle changes using ARA-C or MK1775 alone or in combination, when only the live population was assessed ( Supplementary Figure 3b) . To better assess S-phase progression, we analyzed BrdU incorporation with or without these drugs ( Figure 6a ). As expected, in the presence of ARA-C the percentage of cells in S-phase was significantly increased (Figure 6b, top) , consistent with impaired progression through S-phase. In addition, the extent of BrdU incorporation in those cells in S-phase was diminished (Figure 6b , middle), consistent with stalled replication forks and impaired DNA synthesis. 39 However, with addition of MK1775 the impaired progression through S-phase induced by ARA-C was abrogated. Moreover, a large population of BrdU neg cells with 42N and o4N DNA content emerged in the context of combination therapy (Figures 6a and b, bottom) , suggesting a population of cells that had arrested in S-phase for which DNA synthesis had ceased altogether. 25 Although not identical, we saw similar abrogation of S-phase effects induced by ARA-C in cells in which WEE1 had been knocked down ( Supplementary Figure 3c ). CDK2 is one of the cell-cycle kinases involved in progression through S-phase. 40 Its activity is inhibited by phosphorylation of threonine-14 (T14) and tyrosine-15 (Y15) residues. 41 --43 As expected, CDK2 was phosphorylated in AML cells exposed to ARA-C or HU, but when ARA-C was combined with MK1775, this phosphorylation was abrogated (Figure 6c ). Consistent with activity in the S-phase of the cell cycle, WEE1 inhibition with MK1775 markedly sensitized AML cells to HU, a DNA synthesis inhibitor, which induces S-phase arrest (Figure 6d ).
Inhibition of WEE1 in combination with ARA-C induces more apoptosis than ARA-C alone in AML cell lines and primary AML cells To determine whether the alterations in cell-cycle control were sufficient to lead to cell death, we used flow cytometry to analyze the proportion of cells undergoing apoptosis after exposure to ARA-C and/or MK1775. Staining for Annexin-V and PI exclusion indicates that addition of MK1775 to ARA-C leads to more apoptosis than ARA-C alone (Figure 7a ). We also measured Abbreviations: AML, acute myeloid leukemia; ARA-C, cytarabine. MV4-11 or Molm13 cells were treated as in Figure 5a and the combination index (CI) was calculated for the various dose combinations. CI values less than 1 indicate synergistic inhibition of proliferation.
induction of apoptosis in Molm13 cell lines in which WEE1 had been knocked down, and similarly found a greater percentage of cells undergoing apoptosis in these cells as compared with those expressing a non-silencing control sequence (Figure 7b ). To ensure that the observed combinatorial effect is not limited to immortalized AML cell lines, we also exposed primary AML cells to ARA-C and/or MK1775, and found enhanced induction of apoptosis with the combination as compared with either drug alone (Figure 7c and Supplementary Figure 4 ). We again observed abrogation of inhibitory phosphorylation of CDK2 with WEE1 inhibition, indicating a similar mechanism of action in primary AML cells ( Supplementary Figure 4) . This effect was not universal, though, as 1 of the 4 samples showed no enhancement of apoptosis ( Supplementary Figure 4) .
DISCUSSION
The clinical and molecular heterogeneity of AML remain major challenges in improving outcomes for this disease. In order to objectively and rapidly identify proteins, which can be modulated to enhance the activity of current standard therapy, we queried the entire genome using complementary functional and descriptive assays. Integration of data from these experiments strongly implicates cell-cycle checkpoints as critical determinants of AML cell fate after exposure to ARA-C. WEE1 was among the proteins identified in the genome-wide functional screen, which also appears to be overexpressed in AML cells as compared with normal cells. Genetic and pharmacologic inhibition of WEE1 together with ARA-C inhibited proliferation and induced apoptosis in AML cell lines and primary AML samples, validating the potential of WEE1 as a therapeutic target in AML. Cell-cycle analyses and western blotting confirm that the effect is due to abrogation of the intra-S-phase checkpoint, a function of WEE1 that to our knowledge has not been considered previously from a therapeutics perspective.
These data highlight the power of integrating genome-scale experimentation, and functional genomic screening in particular. While gene expression profiling of tumors and analysis of mutations within cancer genomes have provided a wealth of data and may eventually be used prognostically or to guide therapy, the descriptive nature of the data is difficult to interpret and apply clinically. That is, whether overexpression or mutation of any given gene in a particular tumor may have functional significance or is a viable therapeutic target remains unknown until further experimentation is pursued. By contrast, functional genetic screening identifies molecules based on functional relevance a priori. The approach that we have developed allows cost-effective, high-throughput validation, rapidly narrowing focus for detailed analyses of true positives. In this particular screen, the false positive rate was higher among shRNAs expected to confer chemoresistance, as compared with chemosensitivity ( Figure 3a) . The reasons for this are not entirely clear, as others have performed positive selection screening using shRNA libraries with good results. 44, 45 Differences in methodology may have contributed to our observations, as continuous or repeated drug exposure may be a more effective method for detecting drug resistance-conferring shRNAs. 44, 45 While cell-cycle checkpoints have been studied previously in AML, to our knowledge, this is the first report to document the functional importance of WEE1 in AML. Chk1 has similar effects in arresting the cell cycle in the context of chemotherapy, and its inhibition has been explored therapeutically. 46 WEE1 may prove to be a better therapeutic target, though, as its effects in cell-cycle regulation are direct and specific, whereas Chk1 integrates from and propagates signals through multiple other molecules, including WEE1. MK1775 is in early-phase clinical trials in combination with chemotherapy for solid tumors, and the sideeffect profile is manageable in preliminary reports. 47 We have demonstrated the importance of WEE1 in inducing the intra-S-phase checkpoint in the context of ARA-C, which we propose is critical for AML cell survival during treatment. These data support a model whereby ARA-C treatment results in stalled DNA replication; whereas some cells will commit to apoptosis, others will recover and successfully complete cell-cycle progression. But if inhibition of WEE1 prevents proper recognition of stalled replication, we speculate that replication forks will collapse, leading to S-phase arrest and consequent apoptosis. Our results are somewhat surprising, in that the primary function of WEE1 is considered to be inhibition of cell-cycle progression at the G 2 /M transition of the cell cycle through inhibitory phosphorylation of CDK1 at Y15, 35, 48 whereas we observed abrogation of CDK2 Y15 phosphorylation with WEE1 inhibition in addition to inhibitory phosphorylation of CDK1 (not shown). Our data are consistent with the conserved function of WEE1 orthologs from Arabidopsis, Xenopus and human cells in phosphorylation of CDK2 to regulate progression through S-phase. 49 in AML cells broadens the therapeutic relevance of this molecule, particularly for treatment of AML, which is heavily dependent on the S-phase effects of ARA-C. Inhibition of WEE1 is primarily being explored in patients with abnormal p53 function, as p53 is primarily responsible for the G 1 checkpoint, and cells with impaired p53 function are highly dependent on the G 2 /M checkpoint to maintain genomic integrity. 52 Indeed, cells with impaired p53 function can be sensitized to DNA damage by impairing the G 2 /M checkpoint through inhibition of Chk1 or WEE1. 53 Whereas combining WEE1 inhibition with anthracycline has been shown to be synergistic in solid tumor models, 54 whether inhibition of WEE1 in the context of anthracycline is synergistic in AML cells has yet to be demonstrated. While TP53 is not frequently mutated in AML, its function is often impaired; 55 --57 thus, it is reasonable to hypothesize that WEE1 in combination with anthracyclines would result in synergistic AML cell death. Nonetheless, our data implicating the importance of WEE1 in combination with ARA-C were generated in cell lines that are reported to have functional p53, suggesting that inhibition of WEE1 can be considered for tumors with functional p53.
We have demonstrated that WEE1 inhibition sensitizes AML cells to ARA-C in vitro; however, we cannot conclude that these findings will be broadly applicable to all patients with AML. Indeed, not all of the primary patient samples we tested provided evidence of combinatorial effects, suggesting underlying molecular susceptibility to this combination. Thus, it will be important to develop appropriate, practical biomarkers with which to predict which patients may benefit the most from such a therapeutic strategy. Animal modeling of AML with assessment of pharmacokinetics will provide further data in evaluating the effectiveness of WEE1 inhibition with ARA-C in eliminating AML cells and prolonging survival.
In summary, using integrated genomic analyses, we have identified and validated WEE1 as a potential therapeutic target in AML. These data highlight the power of integrated genomic analyses, which may vastly accelerate the pace of discovery, validation and translation of molecular biology phenomena.
